OXB

Oxford, United Kingdom Founded: 1995 • Age: 31 yrs Listed
Gene therapies for multiple diseases are developed via lentiviral systems.

About OXB

OXB is a publicly listed company based in Oxford (United Kingdom) founded in 1995 by Neill Mackenzie. Gene therapies for multiple diseases are developed via lentiviral systems. It operates on a Managed Services and Professional Services model. The company has 861 employees. OXB has completed 4 acquisitions, including ABL, ABL Europe and Homology Medicines. Its chief executive, as recorded, is Tim Kelly. Its website oxb.com draws about 21 thousand monthly visits. OXB offers products and services including LentiVectorâ„¢ Platform, inAAVateâ„¢ Platform, and CDMO Services. Its focus areas include Biotechnology and Cell and Gene Therapy. Its legal entity is Oxford Biomedica PLC. Its competitors include Ori Biotech and eXmoor; 2 of its 2 listed competitors have raised funding.

Company details

OXB is established as a global leader in cell and gene therapy contract development and manufacturing (CDMO), with over 30 years of expertise in viral vectors. Services are provided to innovative pharmaceutical and biotechnology companies, covering lentivirus, AAV, adenovirus, and other vector types. End-to-end capabilities are offered, from early-stage development to commercialization, supported by robust quality systems and regulatory knowledge. Operations span multiple sectors within healthcare, focusing on enabling life-changing therapies for patients worldwide through advanced manufacturing and development solutions.

  • Headquarters Oxford, United Kingdom
  • Employees 861
  • Founders Neill Mackenzie
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website oxb.com
  • Social LinkedIn X YouTube
  • Legal Name Oxford Biomedica Plc
Key Metrics
  • Annual Revenue
    $227.22 M (USD)
    31.01
    as on Dec 31, 2025
  • Net Profit
    -$40.57 M (USD)
    30.24
    as on Dec 31, 2025
  • EBITDA
    -$12.28 M (USD)
    60.84
    as on Dec 31, 2025
  • Latest Funding Round
    $81.34M (USD), Post-IPO

    Aug 2025

  • Investors
  • Employee Count
    861
  • Investments & Acquisitions
    ABL

    & 3 more

Products & Services of OXB

OXB offers a comprehensive portfolio of products and services, including LentiVector™ Platform, inAAVate™ Platform, and CDMO Services.

LentiVector™ Platform
Viral Vector Technology

Innovative lentiviral gene delivery technology is commercially approved.

inAAVate™ Platform
Viral Vector Technology

Proven AAV vector development ensures high-quality clinical products.

CDMO Services
Contract Development and Manufacturing

End-to-end viral vector manufacturing supports cell therapy clients.

Apps and channels of OXB

its YouTube channel OXB has 153 subscribers and 6 videos.

OXB
YouTube 153 subscribers 6 videos Science & Technology
Open channel

Videos from OXB

The most watched videos on OXB's YouTube channel, OXB (153 subscribers). Click a video to play it here.

Inside Oxbox
1.8K views
Oxford Biomedica’s expanding global footprint and capabilities
606 views
Viral Vector Manufacturing Success Stories - Webinar Recording with Xtalks
313 views
TetraVecta Webinar Recording with XTalks
279 views

More on OXB.

Funding Insights of OXB

  • Total Rounds 4
  • Last Round Post-IPO — $81.34M
  • Investors Count 2

All 4 funding rounds of OXB with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2025$81.34MPost-IPO––
–
Jan 2025Post-IPO––
Sep 2021$68.33MPost-IPO––
–
Apr 2019Unspecified––
Valuation history

2 investors in total: 2 institutional.

Investors in OXB

OXB has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Briarwood Chase Management and Novo Holdings.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
Briarwood Chase Management is focused on long-term global investments.
briarwoodcap.comNew York, United States
Premium access

Investor details for OXB

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of OXB

185 people are tracked at OXB (63 in leadership, 6 in board & advisors, 116 in team); the tracked headcount is 861.

NameRoleGroup
Neill Mackenzie
FounderLeadership
Tim Kelly
CEOLeadership
Heather Preston
Non Executive Director & Board MemberLeadership
Frank Mathias
CEOLeadership
Kyriacos Mitrophanous
Chief Scientific OfficerLeadership
Sandrine Lopes
Senior Director, Head Of Business Development EMEALeadership
Aziz Kagdi Mba, Cmgr Fcmi
Operations Programme DirectorLeadership
Fiona Forsyth (née Sandeman)
Director Clinical OperationsLeadership
Aurélie Charpentier
Director Of Business DevelopmentLeadership
Lucinda Crabtree
Chief Financial OfficerLeadership
Yvonne Sun
Director Of Quality Assurance Operations (gene Therapy Aav)Leadership
Simon Simpkins
Vp, Head Of Analytical Development And QCLeadership
Lisa James
Chief People OfficerLeadership
Sébastien Ribault
Chief Commercial OfficerLeadership
Colin Grugeon
Recruitment Business PartnerLeadership
Thierry Cournez
Chief Operating OfficerLeadership
Mark Caswell
Site Head of US OperationsLeadership
Sharmilee Patel
Head Of Business Development, US ECLeadership
Satpal Griffiths
Senior Director, Analytical ServicesLeadership
Julie Copperthwaite
Head Of Group HR OperationsLeadership

165 more people are available in the full profile.

Premium access

Complete people profiles for OXB

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of OXB

OXB is a publicly listed company on the LSE with ticker symbol OXB in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date04 Nov 2008
  • Listed onOTCMKTS: OXBDF
  • Listed entityOxford BioMedica plc
  • Exchange sectorHealth technology
  • ISINGB00BDFBVT43
  • Share price514.00 GBX · 2026-10-14
  • Market capitalisation622,032,335.00 GBX
  • EPS (diluted, trailing year)-0.34 GBX
  • Volume (last session)1,504

Financials of OXB

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025168.7M GBP-30.1M GBP-9.1M GBP
2024128.8M GBP-43.2M GBP-23.3M GBP
202389.5M GBP-157.5M GBP-60.1M GBP
2022140.0M GBP-39.2M GBP-28.3M GBP
2021142.8M GBP19.0M GBP32.4M GBP
Premium access

Detailed financial statements for OXB

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by OXB

OXB has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include ABL, ABL Europe and Homology Medicines.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Preclinical development services are provided by ABL to biotechnology clients.
abl-europe.comRockville, United States1961Dec 2023••••
Contract research and manufacturing for biologics and vaccines are provided.
ablinc.comRockville, United States1961Sep 2023$15.8M
Developer of gene therapies for rare genetic diseases
homologymedicines.comLexington, United States2015Jan 2022••••
Biotechnology products are developed to enhance immune responses against diseases.
oxti.comFairfield, United States2004Mar 2007$30.91M
Premium access

Complete acquisition details for OXB

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of OXB

8 dated milestones of OXB across 30 years, from founding to its latest funding, stage changes and deals.

  1. Founded OXB is founded.
  2. Acquisition Acquires Oxti.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding First funding round.
  5. Acquisition Acquires Homology Medicines.
  6. Acquisition Acquires ABL.
  7. Acquisition Acquires ABL Europe.
  8. Funding Latest funding round, Post-IPO, of $81.3M.

Competitors of OXB

OXB has 2 listed competitors in our database, 2 of them funded. They include Ori Biotech and eXmoor.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
oribiotech.com2015London, United Kingdom$281.12M52
Software development services are provided for the biopharma sector.
exmoorpharma.com2004Bristol, United Kingdom$51.75M
Cell and gene therapeutic services are provided to biopharmaceutical firms.
Premium access

Detailed competitors of OXB

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of OXB

The website of OXB (oxb.com) receives about 21.1K visits a month and ranks #1,726,571 among all websites worldwide, #2,341 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    21.1K

    ▲ 56.7% vs previous month

  • Unique visitors
    6.1K

    per month

  • Global rank
    #1,726,571

    among all websites

  • Category rank
    #2,341

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with OXB. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pharmaventures.com
100%
View details
accord-healthcare.com
accord-healthcare.com
97%
#1,035,209–
evoxtherapeutics.com
95%
9K#2,464,657View details
pipelinereview.com
pipelinereview.com
94%
–
insights.bio
insights.bio
90%
#986,365–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for OXB

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Oxb

Premium access

Complete news archive for OXB

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about OXB

OXB was founded in 1995 and raised its 1st funding round 24 years after it was founded.

OXB is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.

Tim Kelly is the CEO of OXB, as recorded in our data.

OXB has 861 employees.

Annual revenue of OXB is $227.22M as on Dec 31, 2025.

OXB is established as a global leader in cell and gene therapy contract development and manufacturing (CDMO), with over 30 years of expertise in viral vectors. Services are provided to innovative pharmaceutical and biotechnology companies, covering lentivirus, AAV, adenovirus, and other vector types. End-to-end capabilities are offered, from early-stage development to commercialization, supported by robust quality systems and regulatory knowledge. Operations span multiple sectors within healthcare, focusing on enabling life-changing therapies for patients worldwide through advanced manufacturing and development solutions.

OXB's top competitors include Ori Biotech and eXmoor.

OXB offers LentiVectorâ„¢ Platform, inAAVateâ„¢ Platform, and CDMO Services.

Yes, OXB is publicly traded on LSE under the ticker symbol OXB.

OXB has made 4 acquisitions, including ABL, ABL Europe, and Homology Medicines.

OXB has 2 investors. Key investors include Briarwood Chase Management, and Novo Holdings.

OXB operates through Oxford Biomedica Plc.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available